Skip to main content
OpenTrials
Completed

NCT Number: NCT02658682

Secondary Prevention of Depression Applying an Experimental Attentional Bias Modification Procedure

Depression (Major Depressive Disorder; MDD) has been dubbed "the common cold among the mental illnesses" and it is also a highly recurrent disorder. Secondary prevention has been identified as a key goal in the long-term management of depression. High recurrence rate suggests that there are specific vulnerability factors that increase people's risk for developing repeated episodes of the disorder. Preventive strategies should identify and ameliorate these factors to reduce the individual's risk of subsequent episodes. Biased attention for emotional stimuli is central to the cognitive model where increased sensitivity to negative cues is believed to fuel the negative thoughts and feelings in depression and play a key role in maintaining the illness. Selective biases in attention can be modified by a simple computerized technique; The Attention Bias Modification Task (ABM). This project aims to investigate whether ABM can reduce surrogate and clinical markers of relapse in a large group highly vulnerable to depressive episodes. The effects of ABM, immediately after the two weeks intervention, on three key risk factors for depression will be studied: Residual symptoms, cortisol awakening response and emotion regulation strategies. The participants will be followed up after 1 month, 6 months and 12 months. The hypothesis that ABM will reduce subsequent episodes of low mood over the following 12 months in this group in a manner predicted by early changes in these risk factors will be investigated. It will also be tested if such effects in the lab may be dependent on candidate genes which affect serotonin reuptake and which have been implicated in malleability and emotional learning. Effects on underlying neural correlates of emotion regulation will be studied in an fMRI experiment in a sub-sample and which will also be stratified by serotonin transporter genotype (see also NCT02931487). The predictive value of meta cognitions related to rumination and the possible mediating effects of automatic thoughts and perceived stress will also be investigated in a sub group (see also NCT02648165).

The characterization of the cognitive, genetic and neural mechanisms underlying the ABM effect will have key implications for future treatment development and combination with other treatment modalities like pharmacotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sørlandet Hospital, Department of Psychiatry, Arendal, Aust-Agder, Norway

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Nondepressed subjects (based on the MINI structured interview) with a history of major depression

Exclusion criteria

  • Current or past neurological illness, bipolar disorder, psychosis or drug addiction.

Treatment and study plan

Attention Bias Modification

Behavioral

Computer based Attention Bias Modification

Sham Attention Bias Modification

Behavioral

Computer based Sham Attention Bias Modification

Primary outcomes

  1. Change in residual symptoms of depression. Self report.

    Time frame: At baseline and immediately after ABM intervention (during first week after ABM).

    Beck Depression Inventory

  2. Change in residual symptoms of depression. Clinician rating

    Time frame: At baseline and immediately after ABM intervention (during first week after ABM).

    Hamilton Depression Rating Scale

Secondary outcomes

  1. Recurrence of major depressive episodes

    Time frame: Will be measured 12 month after baseline

    Measured by the MINI structured interview

  2. Changes in Emotion Regulation

    Time frame: At baseline.

    Emotion Regulation Questionnaire (ERQ).

  3. Changes in Rumination

    Time frame: At baseline and 12 months after intervention

    The Rumination Response Scale

  4. Changes in cortisol response.

    Time frame: At baseline, immediately after ABM intervention and one month after intervention.

    Cortisol samples from saliva measured by diural variation (6 samples).

  5. Changes in symptoms of anxiety

    Time frame: At baseline, immediately after ABM intervention (during first week after ABM intervention), 1 month after intervention, 6 months after intervention and 12 months after intervention

    Beck Anxiety Inventory

Other outcomes

  1. Automatic thoughts

    Time frame: At baseline, immediately after ABM intervention (average one day), 1 month after intervention, 6 months after intervention and 12 months after intervention

    Automatic Thought Questionnaire (ATQ)

  2. Changes in perceived stress

    Time frame: At baseline, immediately after ABM intervention (average one day), , 1 month after intervention, 6 months after intervention and 12 months after intervention

    Perceived Stress Scale (PSS).

  3. Meta cognitions

    Time frame: At baseline and 12 months after intervention

    Positive and Negative Beliefs about Rumination scale (PBRS and NBRS)

  4. 5-HTTLPR+A>G polymorphic variation divided by the triallelic functional "high expressive" versus "low expressive" genotype will moderat the effect of ABM on residual symptoms compared to neutral ABM placebo condition

    Time frame: Immediately after ABM intervention.

  5. Brain Derived Neurotrophic Factor (BDNF) val66met polymorphic variation linked to Brian Derived Neurotrophic Factor (BDNF) variation will moderate the effect of ABM on residual symptoms compared to neutral ABM placebo condition

    Time frame: Immediately after ABM intervention.

  6. A serotonergic cumulative Genetic score, including (5-HHTLPR, HTR1A 8rs6295) and HTR 2A (rs 6311) polymorphisms will moderate the effects of ABM on residual symptoms compared to neutral placebo condition

    Time frame: Immediately after ABM intervention.

  7. Change in residual symptoms of depression. Self report

    Time frame: One month after intervention, 6 months after intervention and 12 months after intervention

    Beck Depression Inventory

  8. Change in residual symptoms of depression. Clinical rating

    Time frame: One month after intervention, 6 month after intervention and 12 month after intervention

    Hamilton Depression Rating Scale

  9. Primary outcome measures will be modified by the degree of attentional change during the ABM intervention.

    Time frame: Immediately after the ABM intervention

  10. Primary outcome measures will be modified by executive functioning

    Time frame: At baseline

Sponsors and collaborators

Lead sponsor

University of Oslo

Other

Collaborators

  • Diakonhjemmet Hospital
  • Sorlandet Hospital HF
  • University of Oxford

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2017
First posted
Jan 20, 2016
Registry last updated
Apr 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.